Corticosteroids agents

Table 10. Anti-Parkinson agents. Table 11. Antipsychotic agents. Table 12. Corticosteroid agents. Table 13. Anticoagulant agents.

Budesonide is a potent corticosteroid agent used in the therapy of asthma. It is a glucocorticoid, but has potent mineralocorticoid activity. 

The effects of 1,8 cineole on stimulated human monocyte mediator production were studied in vitro and compared to that of budesonide, a corticosteroid agent with anti-in ammatory and immunosuppressive effects (Juergens et al., 1998a). At therapeutic levels, both substances demonstrated a similar inhibition of the in ammatory mediators leukotriene B4 (LTB4), prostaglandin E2 (PGE2), and interleukin ip (IL ip).This was the rst evidence of a steroid-like inhibition of arachidonic acid metabolism and IL ip production by 1,8 cineole. 

There are hundreds of topical steroid preparations that are available for the treatment of skin diseases. In addition to their aforementioned antiinflammatory effects, topical steroids also exert their effects by vasoconstriction of the capillaries in the superficial dermis and by reduction of cellular mitosis and cell proliferation especially in the basal cell layer of the skin. In addition to the aforementioned systemic side effects, topical steroids can have adverse local effects. Chronic treatment with topical corticosteroids may increase the risk of bacterial and fungal infections. A combination steroid and antibacterial agent can be used to combat this problem. Additional local side effects that can be caused by extended use of topical steroids are epidermal atrophy, acne, glaucoma and cataracts (thus the weakest concentrations should be used in and around the eyes), pigmentation problems, hypertrichosis, allergic contact dermatitis, perioral dermatitis, and granuloma gluteale infantum (251). 

These compounds vary in their specific mechanism of action and often have different effects on the individual patients. Thus, they are generally used in combinations, eg, corticosteroids with an alkylating agent, or an antimetaboUte with a plant alkaloid in a rotating schedule. 

The corticosteroids are administered with caution in older adults because they are more likely to have preexisting conditions such as congestive heart failure, hypertension, osteo-poros s and arthritis which may be worsened by the use of such agents The nurse monitors older adults for exacerbation of existing conditionsduring corticosteroid therapy. In addition, lower dosages may be needed because of the effects of aging, such as decreased muscle mass renal function, and plasma volume. 

There is a decreased effectiveness of ritodrine when the drug is administered with a -adrenergic blocking agent such as propranolol and an increased risk of pulmonary edema when administered with the corticosteroids. Co-administration of ritodrine with the sym-pathomimetics potentiates the effect of ritodrine. Cardiovascular effects (eg, arrhythmias or hypotension) of ritodrine may increase when the drug is administered with diazoxide, general anesthetics, magnesium sulfate, or meperidine... 

Gentian violet solution is used to delineate the areas to be treated. Refrigerant topical anesthesia is used to freeze the skin prior to the procedure. Holding the skin taut, the dermabrader treats one anatomic unit at a time. Post-operatively, patients may have an open or closed dressing system, use antiviral agents, antibacterials and corticosteroids. The re-epithelialization is complete in 5-7 days and residual erythema is common for up to 4 weeks. 

Although both formoterol and salmeterol are effective as add-on therapy for moderate persistent asthma, neither agent should be used as monotherapy for chronic asthma. Patients treated with salmeterol alone are at greater risk of worsening asthma than those treated with inhaled corticosteroids.25,26... 

Corticosteroids are the most potent anti-inflammatory agents available for the treatment of asthma. The efficacy of corticosteroids is due to their ability to affect multiple inflammatory pathways, resulting in the suppression of inflammatory cell activation and function, prevention of microvascular leakage, decreased mucus production, and upregulation of P2-adrenergic receptors.10,18 Clinically, corticosteroids decrease airway inflammation, decrease AHR, decrease mucus production and secretion, and improve the response to P2-agonists.18 Corticosteroids for the treatment of asthma are available in inhaled, oral, and injectable dosage forms. 

Inhaled corticosteroids are not equivalent on a milligram basis however, equivalent doses have been approximated (Table 11-3). Low to moderate doses have been shown to be safe and effective in all age groups. Although some effect is seen from inhaled corticosteroids within 12 hours, 2 weeks of therapy is necessary to see significant clinical effects, and longer treatment periods maybe necessary to see the full effect of these agents on airway inflammation and remodeling. 

Leukotriene modifiers either inhibit 5-lipoxygenase (zileuton) or competitively antagonize the effects of leukotriene D4 (montelukast and zafirlukast). These agents improve FEV, and decrease asthma symptoms, rescue drug use, and exacerbations due to asthma. Although these agents offer the convenience of oral therapy for asthma, they are significantly less effective than low doses of inhaled corticosteroids.2,33... 

Both of these agents have been associated with rare reports of Churg-Strauss syndrome. This syndrome may result from the corticosteroid dose reduction, as it has also been reported when systemic corticosteroids have been reduced or withdrawn in conjunction with the initiation of high-potency inhaled corticosteroids.35... 

Cromolyn and nedocromil are inhaled anti-inflammatory agents that block both the early- and late-phase response. Both agents are considered alternative therapies to inhaled corticosteroids for the treatment of mild persistent asthma however, both are less effective than low doses of inhaled corticosteroids.2,30 The exact mechanism of action of these agents is not understood, but they appear to inhibit mast cell mediator release as well as modulate other inflammatory responses.3... 

In addition to their decreased efficacy compared to corticosteroids, a primary drawback to the use of these agents is... 

Agents targeting the excessive immune response or cytokines involved in IBD are potential treatment options (Table 16-3). Azathioprine and its active metabolite 6-mercaptopurine (6-MP) are inhibitors of purine biosynthesis and reduce IBD-associated GI inflammation. They are most useful for maintaining remission of IBD or reducing the need for long-term use of corticosteroids. Use in active disease is limited by their slow onset of action, which may be as long as 3 to 12 months. Adverse effects associated with azathioprine and 6-MP include hypersensitivity reactions resulting in pancreatitis, fever, rash, hepatitis, and leukopenia.25,26... 

Oral corticosteroids may be used for patients who are unresponsive to sulfasalazine or mesalamine. Prednisone doses of 40 to 60 mg per day (or equivalent) are recommended.1 Azathioprine or 6-MP is used for patients unresponsive to corticosteroids or those who become steroid-dependent. Over a 12-month period, these agents have been shown to reduce the relapse rate to 36% versus 59% seen with placebo.1 Infliximab 5 mg/kg may also be used for patients who are unresponsive to conventional oral therapies and may reduce the need for colectomy after 3 months of treatment.35... 

Corticosteroids have various effects on immune and inflammatory response systems, although their exact mechanism of immunosuppression is not fully understood. It is generally believed that at high doses, the agents are directly lymphotoxic, and at lower doses, the corticosteroids act by inhibiting the production of various cytokines that are necessary to amplify the immune response.11... 

---